These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792 [TBL] [Abstract][Full Text] [Related]
63. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773 [TBL] [Abstract][Full Text] [Related]
64. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. Liu T; Gobburu JVS J Pharm Sci; 2018 Mar; 107(3):942-948. PubMed ID: 29102550 [TBL] [Abstract][Full Text] [Related]
65. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398 [TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics of buprenorphine after intravenous administration in the mouse. Yu S; Zhang X; Sun Y; Peng Y; Johnson J; Mandrell T; Shukla AJ; Laizure SC J Am Assoc Lab Anim Sci; 2006 May; 45(3):12-6. PubMed ID: 16642964 [TBL] [Abstract][Full Text] [Related]
68. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Kharasch ED; Bedynek PS; Hoffer C; Walker A; Whittington D Anesthesiology; 2012 Feb; 116(2):432-47. PubMed ID: 22273859 [TBL] [Abstract][Full Text] [Related]
69. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991 [TBL] [Abstract][Full Text] [Related]
70. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144 [TBL] [Abstract][Full Text] [Related]
71. Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site. Messenger KM; Davis JL; LaFevers DH; Barlow BM; Posner LP Vet Anaesth Analg; 2011 Jul; 38(4):374-84. PubMed ID: 21501371 [TBL] [Abstract][Full Text] [Related]
72. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442 [TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862 [TBL] [Abstract][Full Text] [Related]
74. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Derks M; Fowler S; Kuhlmann O Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849 [TBL] [Abstract][Full Text] [Related]
75. The metabolism and excretion of buprenorphine in humans. Cone EJ; Gorodetzky CW; Yousefnejad D; Buchwald WF; Johnson RE Drug Metab Dispos; 1984; 12(5):577-81. PubMed ID: 6149907 [TBL] [Abstract][Full Text] [Related]
76. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Araki K; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Inoue Y; Tateishi T; Otani K Eur J Clin Pharmacol; 2004 Aug; 60(6):427-30. PubMed ID: 15232663 [TBL] [Abstract][Full Text] [Related]
77. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Peltoniemi MA; Saari TI; Hagelberg NM; Reponen P; Turpeinen M; Laine K; Neuvonen PJ; Olkkola KT Clin Pharmacol Ther; 2011 Aug; 90(2):296-302. PubMed ID: 21716267 [TBL] [Abstract][Full Text] [Related]
78. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Kharasch ED; Walker A; Whittington D; Hoffer C; Bedynek PS Drug Alcohol Depend; 2009 May; 101(3):158-68. PubMed ID: 19232844 [TBL] [Abstract][Full Text] [Related]